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AbstrACt
background There has been little detailed systematic 
consideration of the delivery, setting and outcomes of 
paediatric Outpatient Parenteral Antimicrobial Therapy 
(OPAT), although individual studies report that it is a safe 
and effective treatment.
Objective This scoping review aimed to examine what 
is known about the delivery, settings and outcomes of 
paediatric OPAT and to identify key knowledge deficits.
Design A scoping review using Arksey and O’Malley’s 
framework was undertaken.
Data sources Keywords were identified and used to 
search MEDLINE and CINAHL.
study appraisal methods Primary research studies were 
included if samples comprised children and young people 
21 or under, who had received OPAT at home or in a day 
treatment centre. The Mixed Methods Appraisal Tool was 
used to review the methodological quality of the studies
Main findings From a preliminary pool of 157 articles, 51 
papers were selected for full review. 19 studies fitted the 
inclusion criteria. Factors influencing delivery of OPAT were 
diverse and included child’s condition, home environment, 
child-related factors, parental compliance, training and 
monitoring. There is little consensus as to what constitutes 
success of and adverse events in OPAT.
Conclusions Future studies need to clearly define and 
use success indicators and adverse events in order to 
provide evidence that paediatric OPAT is safe and effective.
Implications Consensus outcomes that include child 
and parent perspectives need to be developed to allow 
a clearer appreciation of a successful paediatric OPAT 
service.
bACkgrOunD   
Children with serious bacterial infections (SBIs) 
have been treated using parenteral antimicro-
bial therapy in an outpatient setting since the 
mid-1970s.1 At this time, the intramuscular 
route was considered to be a clinically safe and 
largely successful means of treating infection.2 
However, advances in intravenous therapy and 
the requirement to protect children from the 
pain associated with the intramuscular injec-
tions led this route to fall into disfavour.
More recently, paediatric Outpatient Paren-
teral Antimicrobial Therapy (OPAT) has been 
defined as the parenteral administration of 
antimicrobials for at least two consecutive 
days without an intervening hospitalisation.3 
This treatment is selectively offered to treat 
SBIs such as pneumonia,4 osteoarticular 
infections5 and low-risk febrile neutropenia.6 
Depending on the child’s condition at presen-
tation, the child may be admitted to hospital 
and receive initial treatment and moni-
toring until deemed sufficiently stable to be 
discharged home on OPAT, or the child may 
be referred immediately for OPAT without 
ever having been admitted to hospital.
Two main approaches to OPAT delivery are 
used depending on the local resources avail-
able. The first is ambulatory and requires the 
child to return to a clinical setting (eg, emer-
gency department or day treatment centre) 
on a daily (or more frequent) basis for assess-
ment and administration of the therapy.7 8 
The second approach is home based, with the 
child being assessed and the therapy admin-
istered in the child’s home either by nursing 
staff or by their parents who have been 
trained to assess and administer the antibi-
otics.4 When the service is delivered by nurses, 
this is usually undertaken by those who are 
strengths and limitations of this study
 ► Identification of methodological weaknesses in 
studies.
 ► Identification of gap in knowledge about parents 
and children’s experience of Outpatient Parenteral 
Antimicrobial Therapy (OPAT), the lack of predeter-
mined success criteria and clarity about what con-
stitutes an adverse event.
 ► Due to the variable quality of the evidence base, 
strong conclusions regarding the delivery, settings 
and outcomes of OPAT cannot be made.
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either part of a specialised OPAT team of community 
nurses,9 10 or those within a broader community role such 
as ‘hospital at home’.11 12
A variety of patient and healthcare benefits are poten-
tially associated with OPAT; most notably for health 
services is that OPAT is considered to be a more cost-ef-
fective option when compared with continued inpatient 
care.13 Other benefits include ‘parent and patient satisfac-
tion, psychological well-being, return to school/employ-
ment, reductions in healthcare-associated infection and 
cost savings’ (Patel et al, p361).3
Given that there has been little consideration of the 
direct and indirect benefits, disadvantages and broader 
outcomes of paediatric OPAT, a scoping review was 
conducted to examine what is known about OPAT in 
terms of delivery, settings and outcomes, and to iden-
tify key areas of deficits in knowledge. Specifically, this 
scoping review explored primary research that exam-
ined OPAT delivered to children and young people aged 
21 or under, who had received OPAT in a home or day 
treatment centre, of which at least 80% of treatment was 
intravenous.
MethOD
A scoping review was undertaken as the intention was to 
explore and map the key concepts and to identify gaps in 
research related to paediatric OPAT. The scoping review 
was conducted following Arksey and O’Malley’s frame-
work,14 which was modified to allow more flexible and 
robust reporting of the results.15–17 These modifications 
included: (1) an iterative approach to refine our search 
strategy and inclusion criteria; (2) an assessment of 
methodological quality was undertaken using the Mixed 
Methods Appraisal Tool (MMAT)18 and (3) in the absence 
of EQUATOR guidance on reporting we were guided by 
recommendations made by the Joanna Briggs Institute.19
Inclusion criteria and types of sources
The inclusion and exclusion criteria are shown in table 1. 
No date restrictions were applied to the search.
The search terms were generated based on consider-
ation of: the population (children and young people 
under the age of 21 years), the ‘concept’ under inves-
tigation (parenteral antimicrobial treatment) and the 
context (home-based or outpatient-based care). Keywords 
and terms identified by the authors were used to search 
PubMed and CINAHL. Further keywords were then iden-
tified and the new search list was used to search Google 
Scholar to generate a comprehensive final set of search 
terms (table 2).
search strategy
Major databases consulted for the indexed published 
literature were MEDLINE and CINAHL. Further arti-
cles not identified in the results of the above strategies 
were added if identified by other means (eg, cited by a 
related article, identified on a World Wide Web search). 
The search was initially undertaken in February 2017 and 
updated in July 2017 and was supported by an expert 
librarian (full electronic search strategy available on 
request). A data extraction sheet was developed and iter-
atively refined and included the following broad catego-
ries: delivery, setting and outcomes. In line with the aims 
of a scoping review, all outcomes of paediatric outpatient 
treatment were included in the data extraction sheet.
Appraisal of study quality
The MMAT18 was used to review, but not score, the meth-
odological quality of the studies. In 7 of the 19 studies, it 
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
1. Primary research studies.
2. Articles in peer-reviewed 
journals.
3. Published in English.
4. Data are presented from 
children and young 
people aged 21 years or 
under (and are reported 
separately from adults' 
data).
5. Children and young people 
who received Outpatient 
Parenteral Antimicrobial 
Therapy treatment did 
so in their home or a day 
treatment centre and 
data from inpatients and 
outpatients were reported 
separately.
6. Children and young people 
received at least 80% of 
treatment intravenously.
7. Data from intramuscular 
and intravenous treatment 
reported separately.
1. Studies conducted in 
developing/low-income 
settings.
2. The full text of the article 
was unavailable.
3. Case studies, reviews, 
guidelines, poster, 
abstracts, commentaries 
and editorials.
Table 2 Search terms (by population, concept, context)
OPAT
OR paediatric outpatient parenteral 
antimicrobial therapy
Population (<21 years)  ► Paediatric OR pediatric OR infant OR child* OR adolesce*
 ► Infection OR infectious disease
Concept (Intervention)  ► Antibiotic OR antimicrobial AND (agent OR therapy OR 
prescri* OR manage*)
 ► Parenteral OR intravenous infusion OR home infusion
Context (Setting)  ► Outpatient OR home OR ambulatory OR community
 o
n
 19 Novem
ber 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-021603 on 15 November 2018. Downloaded from 
3Carter B, et al. BMJ Open 2018;8:e021603. doi:10.1136/bmjopen-2018-021603
Open access
was not completely clear that the collected data adequately 
allowed the research question to be answered. Other key 
quality issues related to completeness of outcome data, 
appropriateness of measurements and acceptability of 
response rate (see table 3).
results
Overview of the studies
A preliminary pool of 157 articles were identified. Titles 
and abstracts were reviewed by two lead reviewers and 
where there was disagreement a third reviewer was used; 
51 papers were selected for full review, from which 19 
were identified as having good fit with the inclusion 
criteria and the objective of the review (see figure 1).
A condensed summary chart detailing the study 
design, sample, requirements, setting and delivery of 
the 19 studies included in the review is available as an 
online supplementary file. The review of studies via the 
MMAT revealed the quality as fair (see table 3).
Data were international, reporting on studies undertaken 
in the USA,5 8 10 13 20–23 Canada,6 7 9 Spain,11 24 Australia,12 25 
Ireland,4 India,26, Israel27 and the Netherlands.28
The studies included in the review had adopted a 
record review design with the exception of three cohort 
studies,7 11 12 two randomised control trials,25 26 an online 
survey20 and a pilot programme.6
All study populations comprised children and/or 
young people aged 1 week to 21 years, with the exception 
of one study which presented data from an online survey 
of paediatric physicians.20 Sample sizes ranged from 728 
to 2687.21
Delivery of service: target population, indications for 
treatment, factors influencing delivery
The studies were mixed in terms of whether the studied 
cohort had a common underlying condition as well as the 
infective indication for receiving OPAT. Only four studies 
had a specific focus on one such condition: cancer6 25 
and cystic fibrosis.4 28 The remaining studies had either 
no specific underlying condition reported5 7–10 21–23 or the 
children had a range of underlying conditions (such as 
gastrointestinal diseases and HIV infection).11–13 20 24 26 27
In terms of the infective indications for treatment, half 
of services delivered OPAT for a wide range of infection 
(eg, respiratory, blood stream, urinary and musculo-
skeletal).8 10–13 20–23 The remaining half were focused on 
a single indication for treatment, such as urinary tract 
infections.4–7 9 24–28
The key consideration in determining the suitability 
of the child for OPAT was the presence of infection. 
Other factors included the stability of the child’s condi-
tion7 9 11 24 26 and the home environment, either in generic 
terms20 or more specifically such as the need for the home 
environment to be ‘stable’10 and appropriately resourced 
in terms of refrigerator and/or telephone.8 10 11 25 26 The 
location of the home was specifically reported as influen-
tial in determining access to OPAT by four studies11 25–27 
and, although, this was not clearly reported, it is likely 
that this was relevant in other studies where specialist 
home-based teams delivered OPAT.
Parental compliance/reliability was also reported 
as either an inclusion factor8 11 20 26 and/or the lack 
of these qualities as an exclusion factor.9 10 Parents 
were trained to administer medication to their child 
in six studies.4 6 11 22 24 27 In all of these studies, all chil-
dren had a pre-existing condition. However, even when 
professionals were responsible for the administration 
of medication, parents received training to: assess for 
complications4 10 11 22 28; to check the child’s tempera-
ture,9 26 deterioration27; inspect the intravenous site8 and 
troubleshoot.6 Five studies reported that training parents 
required a period of time in hospital before discharge to 
OPAT4 10 11 22 28 and one study reported that a period of 
hospitalisation was needed to check for drug reactions.23
Support for parents or carers varied across the studies 
depending on whether the child was receiving home-
based or ambulatory care. For children in the home 
setting, support varied from daily phone calls and home 
visits as needed,11 initial daily or twice daily visits,12 22 25 
visits about every 2.9 days27 and 24 hours access to profes-
sional support.4–6 27 For children receiving ambulato-
ry-based OPAT, parents were advised to return to the 
emergency department and/or readmitted if they had 
concerns.8 25
setting
In most studies, the family home was the setting for the 
delivery of OPAT.4 6 10–13 22–25 27 28 The remaining studies 
were set in various outpatient settings: day treatment 
centres,7 9 a combination of hospital outpatient/local 
clinics26 or emergency department.8 In three studies, the 
location was not reported or unclear.5 20 21 Little detail was 
provided about the outpatient settings or the actual suit-
ability, difficulties or challenges of the home as a setting 
for OPAT.
Outcomes
No studies reported a priori criteria for success of paedi-
atric OPAT. ‘Success’ was therefore implied in terms of 
the percentage/number of children completing OPAT as 
home based or outpatients13 or through reports of what 
percentage of episodes of treatment were completed 
at home.11 Other studies claimed that home treatment 
improved the child’s condition compared with previous 
hospital-based courses of treatment,28 or implied success 
through noting that all ambulatory patients returned for 
scheduled re-evaluation within 24 hours of commencing 
OPAT/initial discharge.8
Clinical complications such as line failures, rehospi-
talisation and adverse drug reactions (ADRs) were not 
consistently reported as adverse events (AEs) although 
these have been identified as such in the Summary Chart.
The reporting of hospitalisation/readmission was 
inconsistent. Although some studies reported the number 
of children who were hospitalised after commencing 
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OPAT,3 7 9–13 22 23 25 26 others reported the number of 
treatment courses that required unplanned hospitalisa-
tion.5 21 24 Hospitalisation rates varied ranging from 4%12 to 
22%27 of patients and between 26%5 and 29%22 of courses. 
Children were hospitalised as a result of being ‘unrespon-
sive to treatment’ (22%)27, ‘inadequate clinical response’ 
(1%)12, ‘exacerbation of underlying condition’ (7%)11, 
‘poor evolution of infectious disease' (3%),11 ‘deteriora-
tion’ (0.6%),4 fever24 26 and the need to ‘complete course 
of intravenous’.22 Catheter associated complications were 
also linked to hospitalisation.5 13 21 23 24 Other reasons 
for hospitalisation included ADRs and surgical manage-
ment,5 21 seizures and bleeding,26 gastro-oesophageal 
reflux and positive blood culture result.9 In two studies 
the reason for admission was less clear.7 10 Unplanned 
medical care visits were reported in two studies with 17 
out of 98 (17%) children having an unplanned visit23 and 
17 (48%) having one or more unplanned visits.10
The number of other catheter-related complications 
was reported by five studies5 12 22 23 27; only one study 
reported no catheter-related complications.6 Extravasa-
tion, displacement and other intravenous access issues 
were reported by 5 studies.7–9 11 28 Poor technique and/
or technical problems were reported by two studies.11 28
The definitions and reporting of ADRs was inconsis-
tent between studies. Four studies reported that no ADRs 
occurred,6 8 25 27 and others provided generic reports of 
ADRs. For example, 25% of children experiencing OPAT 
complications were reported as being associated with 
the use of highly bioavailable antibiotics.21 Two studies 
(11%) provided more detailed reports of ADRs: in one 
study, ADRs were associated with 70 (29%) courses and, 
of these, early discontinuation of antibiotics was reported 
in 58 courses of treatment22 and in the other study ADRs 
were associated with inappropriate choice of drug (6%) 
and inappropriate dose or duration of treatment (26%), 
although the authors also reported that no adverse anti-
biotic-related events necessitated change or cessation of 
antibiotic or hospital readmission.12
Seven studies reported on satisfaction (parental satis-
faction6 7 25 27 28, children’s satisfaction27 28), although 
the mechanisms of data collection were often unclear 
or unreported. In one study, some parents (32%) were 
worried about taking their febrile child home and 
20% were worried about taking their child home with 
indwelling intravenous access.7 In another study, some 
mothers of children aged 6–12 years were anxious about 
accepting the responsibility of their child’s treatment and 
concerned about the stress that home-based care would 
create for the family.28 The 12–18 year olds in this study 
described liking home-based care due to the lack of 
disruption to home and school life, but reported missing 
the contact with staff and other patients that occurred 
when they were inpatients. In another study, children 
aged 10 or over completed questionnaires assessing 
their quality of life. Those who were treated at home had 
significantly better appetites and slept better compared 
with those who were treated in hospital.25
Six studies concluded that OPAT is more cost-effective 
than conventional inpatient treatment6 7 10–13; two studies 
Figure 1 Flow diagram for scoping review process (from Joanna Briggs  Institute manual).
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noted that the cost-effectiveness calculations did not 
account for the costs associated with complications10 or 
the direct cost(s) to families.6
DIsCussIOn
This scoping review has systematically examined the 
empirical evidence regarding the delivery, settings and 
outcomes of paediatric OPAT. The quality review revealed 
that the studies are generally fair quality. The operation-
alisation of specific definitions/treatments varied widely 
and the reporting of who gave treatment and the setting 
was often unclear.
The factors influencing the delivery of OPAT were 
diverse and included: service-related issues including 
staffing and monitoring; child-related factors such as age, 
nature of infection, clinical status; and home/parent-re-
lated factors such home environment, parental compli-
ance and training.
In a systematic review comparing home-based versus 
hospital-based treatment with intravenous antibiotics 
in children, the authors concluded that data about 
the safety of treatment were scarce.29 In addition to a 
scarcity of data, this review found that there is a lack 
of clarity and consensus as to what constitutes success 
in OPAT making comparison across studies difficult; 
however, individual studies report that OPAT is safe.5–7 
12 27 There is also a lack of clarity and consensus in 
the definition and reporting of AEs. There was little 
acknowledgement that although problematic, defining 
AEs is necessary or acknowledging that for one type 
of AE -ADRs- objective criteria do exist and could be 
used. Conclusions about the success of OPAT have been 
drawn despite evidence of AEs (which were ill defined, 
yet occurred in most studies) and readmissions (which 
were reported in different ways, and likewise occurred 
in most studies).
In terms of key knowledge deficits within the literature 
we scoped for this review, most of the studies were retro-
spective and follow-up data examining health outcomes 
over time are lacking. We also know little about parents 
and children’s experience of OPAT. There is little reflec-
tion about the factors which may influence experience 
such as the child’s age, nature of infection, family circum-
stances and the educational level of parents. Additionally, 
considering the fact that infection has a higher incidence 
in families of lower socioeconomic status,30 31 there is 
little detail about whether these families are excluded 
from OPAT or, if in receipt, how they fare in comparison 
to families in better circumstances. We know little of chil-
dren who were not selected for OPAT or parents and chil-
dren who declined this treatment and the reasons why. In 
agreement with the recent systematic review comparing 
home-based versus hospital-based treatment, we likewise 
conclude that although studies report patients to be safely 
treated at home, generalisation to all patients is difficult 
due to selection bias29
The evidence base for the economic benefits of OPAT 
is poorly and inconsistently presented and does not take 
account of any shift of economic burden onto the families.
strengths and limitations
This scoping review has used a robust and iterative meth-
odological approach and included an analysis of study 
quality. However, the variable quality of the evidence base 
means that strong conclusions regarding the delivery, 
settings and outcomes of OPAT for children cannot be 
made. Conclusions are also complicated to draw due to 
the diversity in terms of the age of children receiving 
treatment, children’s underlying conditions, indications 
for treatment and the delivery of treatment. Our focus 
was outpatient care, therefore, our findings do not reflect 
comparison with inpatient care.
Implications for research
Future studies need to clearly define success indicators and 
AEs in order to substantiate claims that OPAT for children 
is safe and effective. Specifically, hospitalisation, unexpected 
catheter-related complications, extravasation and antibiotic 
complications should be reported as AEs. To allow compar-
ison between studies and pooling of data from different 
cohorts, the definitions for such AEs need to be agreed by 
healthcare professionals delivering adult and paediatric 
OPAT care.
Numerous knowledge deficits need to be addressed. 
There is a need for follow-up data tracking the trajectory 
of patient’s interactions with healthcare providers over 
time. Future research of a qualitative nature needs to 
be conducted with children and young people receiving 
OPAT, and their parents in order to explore their experi-
ences of receiving this treatment. A thorough cost-benefit 
analysis needs to conducted that includes a consideration 
of the economic impact on the family.
Implications for practice
Parental and child perspectives should be sought to iden-
tify how they can best be supported. Despite the apparent 
professional confidence in the success and benefits of 
OPAT for children, it should not be assumed that all 
families will choose OPAT or that it will be the most 
appropriate intervention. Clear, consensus outcomes that 
include outcomes of importance to the children and their 
parents need to be developed to allow a clearer apprecia-
tion of a successful OPAT service.
COnClusIOn
Further work that includes the perspectives of children 
and parents and which uses clearly defined indicators will 
improve the evidence base for the efficacy and safety of 
pOPAT.
PAtIent AnD PublIC InvOlveMent
Neither patients nor the public were involved in the 
scoping review process. 
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